{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saline+Comparator&page=2",
    "query": {
      "intervention": "Saline Comparator",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 250,
    "total_pages": 25,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saline+Comparator&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saline+Comparator&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-30T06:43:19.602Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02953587",
      "title": "Effect of Ghrelin on Glucose Metabolism After Bariatric Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Oral Glucose Tolerance Test (OGTT)",
          "type": "PROCEDURE"
        },
        {
          "name": "Human Ghrelin",
          "type": "DRUG"
        },
        {
          "name": "Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "21 Years to 65 Years"
      },
      "enrollment_count": 70,
      "start_date": "2016-09",
      "completion_date": "2023-01-30",
      "has_results": false,
      "last_update_posted_date": "2023-02-08",
      "last_synced_at": "2026-09-30T06:43:19.602Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02953587"
    },
    {
      "nct_id": "NCT01052506",
      "title": "BIIB033 Single Ascending Dose Study in Healthy Volunteer Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "BIIB033",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "25 Years to 55 Years"
      },
      "enrollment_count": 72,
      "start_date": "2010-01",
      "completion_date": "2011-10",
      "has_results": false,
      "last_update_posted_date": "2017-01-09",
      "last_synced_at": "2026-09-30T06:43:19.602Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01052506"
    },
    {
      "nct_id": "NCT02334436",
      "title": "A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV-002",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Glabellar Frown Lines"
      ],
      "interventions": [
        {
          "name": "Botulinum toxin, Type A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "0.9% sterile, unpreserved saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Evolus, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 324,
      "start_date": "2015-01",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2019-03-27",
      "last_synced_at": "2026-09-30T06:43:19.602Z",
      "location_count": 1,
      "location_summary": "Beverly Hills, California",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02334436"
    },
    {
      "nct_id": "NCT01221246",
      "title": "Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stroke"
      ],
      "interventions": [
        {
          "name": "GM602",
          "type": "DRUG"
        },
        {
          "name": "Placebo Comparator",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genervon Biopharmaceuticals, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 34,
      "start_date": "2011-03-08",
      "completion_date": "2016-07-07",
      "has_results": false,
      "last_update_posted_date": "2019-08-12",
      "last_synced_at": "2026-09-30T06:43:19.602Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Newport Beach, California • Pasadena, California + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01221246"
    },
    {
      "nct_id": "NCT04725188",
      "title": "Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Non Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab/Vibostolimab coformulation",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 255,
      "start_date": "2021-04-20",
      "completion_date": "2024-10-17",
      "has_results": true,
      "last_update_posted_date": "2025-08-15",
      "last_synced_at": "2026-09-30T06:43:19.602Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • Peoria, Illinois • Lexington, Kentucky + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Hattiesburg",
          "state": "Mississippi"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04725188"
    },
    {
      "nct_id": "NCT02591173",
      "title": "Blood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic Failure",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Autonomic Nervous System Disorders",
        "Pure Autonomic Failure",
        "Shy-Drager Syndrome",
        "Orthostatic Hypotension, Dysautonomic"
      ],
      "interventions": [
        {
          "name": "Angiotensin-(1-7)",
          "type": "DRUG"
        },
        {
          "name": "Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 7,
      "start_date": "2016-02",
      "completion_date": "2020-07",
      "has_results": false,
      "last_update_posted_date": "2021-01-12",
      "last_synced_at": "2026-09-30T06:43:19.602Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02591173"
    },
    {
      "nct_id": "NCT02762760",
      "title": "AP-011 Study to Evaluate the Safety of a Single Intra-articular Injection of Ampion™ for Arthritis of the Basal Thumb Joint",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Osteoarthritis of the Hand"
      ],
      "interventions": [
        {
          "name": "AMPION™",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Saline",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Ampio Pharmaceuticals. Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "40 Years to 85 Years"
      },
      "enrollment_count": 15,
      "start_date": "2016-05",
      "completion_date": "2016-11",
      "has_results": false,
      "last_update_posted_date": "2016-11-15",
      "last_synced_at": "2026-09-30T06:43:19.602Z",
      "location_count": 1,
      "location_summary": "Englewood, Colorado",
      "locations": [
        {
          "city": "Englewood",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02762760"
    },
    {
      "nct_id": "NCT02646475",
      "title": "Metabolic Effects of Angiotensin-(1-7)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Obesity",
        "Insulin Resistance",
        "Hypertension",
        "Metabolic Cardiovascular Syndrome"
      ],
      "interventions": [
        {
          "name": "Angiotensin-(1-7)",
          "type": "DRUG"
        },
        {
          "name": "Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 26,
      "start_date": "2016-02",
      "completion_date": "2029-12",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-09-30T06:43:19.602Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02646475"
    },
    {
      "nct_id": "NCT02661347",
      "title": "Transcranial Direct Current Stimulation for Hallucinations in First-Episode Schizophrenia",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizophreniform",
        "Schizoaffective Disorder",
        "Psychosis Not Otherwise Specified (NOS)"
      ],
      "interventions": [
        {
          "name": "Risperidone",
          "type": "DRUG"
        },
        {
          "name": "tDCS",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Northwell Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "15 Years to 40 Years"
      },
      "enrollment_count": 0,
      "start_date": "2016-02",
      "completion_date": "2016-12-01",
      "has_results": false,
      "last_update_posted_date": "2018-03-13",
      "last_synced_at": "2026-09-30T06:43:19.602Z",
      "location_count": 1,
      "location_summary": "Glen Oaks, New York",
      "locations": [
        {
          "city": "Glen Oaks",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02661347"
    },
    {
      "nct_id": "NCT04540913",
      "title": "RHA® 3 Versus Restylane-L® for Lip Augmentation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [],
      "conditions": [
        "Lip Augmentation",
        "Lip"
      ],
      "interventions": [
        {
          "name": "RHA 3",
          "type": "DEVICE"
        },
        {
          "name": "Restylane-L",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Teoxane SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 202,
      "start_date": "2020-10-22",
      "completion_date": "2022-09-07",
      "has_results": true,
      "last_update_posted_date": "2025-02-03",
      "last_synced_at": "2026-09-30T06:43:19.602Z",
      "location_count": 1,
      "location_summary": "Bradenton, Florida",
      "locations": [
        {
          "city": "Bradenton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04540913"
    }
  ]
}